CALMponin – Novel markers for the diagnosis and prognosis of breast cancer
The invention is based on the finding that the proteins Calmodulin-like protein 5 (CALML5) and Calponin-h2 (CNN2) are upregulated in the nuclear matrix of human breast cancer tissue whereas both are absent in healthy human breast tissue and benign controls. Thus, the two proteins may serve as novel markers for breast cancer.
Comparing blood levels of patients with breast cancer, patients with benign breast diseases and age-matched healthy controls the use of CNN2 in human blood demonstrated to be a highly specific and sensitive biomarker for the early detection of human breast cancer in women of all ages. As CALML5 can also be found in human blood, a blood based assay identifying breast cancer patients by analysing the level of CALML5 is currently explored. Furthermore, this method may be used for the determination of a patient`s prognosis and of a therapy efficacy within the scope of personalized medicine.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
